Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues.
Achilles Therapeutics brings together four scientific Founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
Location: United Kingdom, England, London
Employees: 201-500
Total raised: $437.09M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | RA Capital... | racap.com |
| - | Albion Cap... | albion.cap... |
| - | Perceptive... | perceptive... |
| - | Syncona Pa... | synconaltd... |
| - | UCL Techno... | ucltf.co.u... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 31.03.2021 | - | $175M | - |
| 20.11.2020 | Series C | $69.81M | - |
| 19.11.2020 | Series C | $69.81M | - |
| 03.09.2019 | Series B | $122.46M | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 11.05.2023 | Achilles Therapeutics’ New Immunogenicity Prediction Applica... | – New AI module delivers a “Target-to-T cell” approach for revolutionizing the identification and pr... | aithority.... |
| 07.02.2023 | Investor Syncona blames bear market's ravaging of British bi... | Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting sha... | fiercebiot... |
| 19.12.2022 | Achilles Therapeutics presents encouraging Phase I/IIa updat... | Achilles brings together world-leading expertise in tumour sequencing and immune response to devel... | ucltf.co.u... |
| 31.03.2021 | Achilles Therapeutics Announces Pricing of Initial Public Of... | J.P. Morgan, BofA Securities and Piper Sandler are acting as joint book-running managers for the o... | ucltf.co.u... |
| 31.03.2021 | Achilles Therapeutics’ IPO nabs $175M to bring cell therapie... | A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another... | medcitynew... |
| 19.11.2020 | SYNCONA LIMITED Syncona : Achilles Therapeutics Raises £52.... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalis... | marketscre... |
| 19.11.2020 | Syncona : Achilles Therapeutics Raises £52.7 Million in an O... | Achilles Therapeutics ('Achilles'), a clinical-stage biopharmaceutical company developing personalis... | marketscre... |
| 04.09.2019 | Achilles Therapeutics raises $120M in Series B round for can... | The company said proceeds for the round will be used to launch two clinical trials of its product ca... | medcitynew... |
| 04.09.2019 | Achilles Therapeutics raises £100m in Series B | Proceeds from this financing will deliver two human proof-of-concept studies using a unique personal... | ucltf.co.u... |
| 03.09.2019 | Achilles Therapeutics Raises £100M in Series B Funding | Achilles Therapeutics, a Stevenage, UK-based biopharmaceutical company developing personalized cance... | finsmes.co... |
Show more